LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
The Board of Directors (the “Board”) of Lantheus Holdings, Inc. (the “Company”) has appointed Gary J. Pruden, Kenneth J. Pucel and Dr.JamesH. Thrall to serve as members of the Board, effective as of February26, 2018.
| • | Gary Pruden, age 56, has over 30 years of experience in the global healthcare industry. Mr.Pruden held a number of senior commercial leadership positions across both the medical device and pharmaceutical sectors of Johnson& Johnson (“J&J”) from 1985 until 2017, including as a member of the Executive Committee of J&J, where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. |
| • | Ken Pucel, age 51, has been the Executive Vice President of Global Operations, Engineering& Lean, at Polaris Industries Inc. since December1, 2014. Previously, Mr.Pucel was with Boston Scientific Corporation (“BSC”), a global provider of medical solutions, where he held positions of increasing responsibility, most recently as Executive Vice President of Global Operations, Quality and Technology from 2012 through 2014, and as a member of BSC’s Executive Committee from 2004 through 2014. |
| • | Dr.Jim Thrall, age 74, currently holds the Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Dr.Thrall is also a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. |
Messrs. Pruden and Pucel and Dr.Thrall were each appointed as a ClassIII Director, with an initial term expiring at the Company’s upcoming 2018 annual meeting of stockholders. To accommodate the appointment of these new directors, the Board increased its size to ten directors.
The Board also appointed the new directors to the following committees of the Board: Mr.Pruden to the Audit Committee and the Financing and Strategy Committee; Mr.Pucel to the Compensation Committee; and Dr.Thrall to the Nominating and Corporate Governance Committee.
Each of these new directors will receive the same cash and equity compensation, expense reimbursement and indemnification rights that the Company provides to its other non-employee members of the Board. Specifically, each will be compensated for his services as a director through Board fees of $50,000 per calendar year (prorated for 2018) and reimbursement for out-of-pocket expenses incurred in connection with rendering those services for so long as he serves as a director. In addition: Mr.Pruden will receive annual fees of $10,000 and $5,000 (each, prorated for 2018) for service as a member of the Audit Committee and the Financing and Strategy Committee, respectively; Mr.Pucel will receive an annual fee of $7,500 (prorated for 2018) for service as a member of the Compensation Committee; and Dr.Thrall will receive an annual fee of $5,000 (prorated for 2018) for service as a member of the Nominating and Corporate Governance Committee.
A copy of the Company’s press release, dated February27, 2018, announcing the appointment of Gary Pruden, Kenneth Pucel and Dr.James Thrall to its Board of Directors, is attached hereto as Exhibit 99.1.
| Item 5.02 | Financial Statements and Exhibits |
Lantheus Holdings, Inc. ExhibitEX-99.1 2 d540795dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica,…To view the full exhibit click here
About LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
